Improving patients' lives through better healthcare begins with a commitment to innovation. Our research and development pipeline is where we put that commitment to work. Takeda Global Research & Development Center, Inc. dedicates its resources to the Takeda product pipeline in an effort to improve people’s lives. As a research-based pharmaceutical company efforts are currently focused on preclinical work and clinical development activities.
| Compound |
Therapeutic Area |
Stage |
| alogliptin |
Diabetes mellitus |
NDA submitted |
| TAK-491 |
Hypertension |
Phase 3 |
| Hematide |
Anemia associated with chronic renal failure (CRF) |
Phase 3 |
| LuAA21004 |
Mood and anxiety disorders |
Phase 3 |
| SYR-322-4833 |
Diabetes mellitus |
NDA submitted |
| MLNM002 |
Crohn’s and Ulcerative Colitis |
Phase 3 |